Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma

NCT04784247 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Advanced Sarcoma

Interventions

DRUG: Lenvatinib
DRUG: Pembrolizumab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

Merck Sharp & Dohme LLC
Parker Institute for Cancer Immunotherapy